S11 E01 ASCO 2025: What's New for MBC?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
S11 E01 ASCO 2025: What's New for MBC?
-
ナレーター：
-
著者：
Send us Fan Mail
In our Season 11 opening episode, we’re bringing you the latest updates from the 2025 ASCO Annual Meeting on metastatic breast cancer. Dr. Ashley Schreier, breast oncologist at Weill Cornell Medicine, breaks down key research and explains what it could mean for people living with MBC.
Topics include:
- Research results for hormone therapy options like camizestrant
- The role of ESR1 mutation testing
- Results from treatment combinations like Enhertu and Perjeta, and Trodelvy and Keytruda
- How to navigate clinical trial access
- Tips for staying hopeful while exploring treatment options
Whether you’re a patient, caregiver, or advocate, this episode is packed with insights to help you stay informed and empowered.
We’re so happy you joined us! If this conversation resonated with you please share it with someone who might need it. Don't forget to like and subscribe here to follow us on your favorite podcast platform so you never miss an episode. You can find more episodes, resources and ways to get involved on our website Our MBC Life. Have a topic you’d like us to cover? Email us at ourmbclife@sharecancersupport.org. And don’t forget to follow us on our socials @ourmbclife.
Remember you are not alone.